{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Nifenalol is the beta-receptor antagonist. It has optical isomers. The racemic mixture and the levo-isomer are active in antagonizing beta-receptors, but the dextro-isomer is inactive. The levo-isomer seems to be about twice as active in blocking beta-receptors as the racemate. Nifenalol is virtually devoid of local anesthetic properties in contrast to procaine, propranolol, and butidrine. Nifenalol exacerbated the fighting behavior in male mice by foot-shock. Nifenalol has been studied in patients with coronary artery disease. It afforded the coronary patient good protection against angina and ischemic changes in the EKG. It was further noted that nifenalol had no antiarrhythmic action and that it was devoid of evident side effects. Nifenalol possessed weak action against tremorine and oxotremorine induced tremor.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
semisynthetic C3 acetyl ester of the aglycone strophanthidin. Acetylstrophanthidin inhibits sodium-potassium adenosinetriphosphatase (Na -K ATPase) and causes an inotropic effect. The effect of acetylstrophanthidin is first seen within half a minute to five minutes and becomes maximal in about ten minutes. This rapid action obviates the effect of time, which is so important for subsidence of precipitationg causes of cardiac failure. Severe pulmonic, coronary, and aortic valvular disease, as well as old age, tended to predispose the patients to unusual acetylstrophanthidin sensitivity. Acetylstrophanthidin may cause nausea and vomiting.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Testosterone succinate (Testosterone hemisuccinate) is a negatively charged derivative of Testosterone. It has being shown that Testosterone succinate induced relaxation of rat aorta, the effect was androgen structure specific and involved K+ channel activation. Testosterone succinate has being studied with respect to its antiviral activity.
Status:
US Previously Marketed
Source:
IOMERVU by BRACCO
(2024)
Source URL:
First approved in 2022
Source:
Iomeron by BIPSO GmbH
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
Iomeprol is a nonionic, monomeric iodinated contrast medium. Iomeprol helps optimize images obtained with sophisticated multidetector computed tomography (MDCT) technology, especially for neurological, brain, liver, cardiac and vascular scanning. The mechanism of action of Iomeprol is as a X-Ray Contrast Activity. Launched by the Bracco Group in 1995, Iomeprol (Iomeron) currently is registered in more than 40 countries worldwide, including all major European markets, Japan, and major Middle East and Asian Pacific countries.
Status:
US Previously Marketed
Source:
PRESTALIA by ADHERA
(2015)
Source URL:
First approved in 2015
Source:
PRESTALIA by ADHERA
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Perindopril arginine is a stable L-arginine salt of perindopril. Perindopril, a pro-drug, is hydrolyzed to perindoprilat, which inhibits ACE in humans and in animals. It is indicated for the treatment of hypertension, heart failure and coronary artery disease. Perindopril arginine may be used in monotherapy or in combination with other classes of antihypertensive therapy.
Status:
US Previously Marketed
Source:
GENESA by GENSIA AUTOMEDICS
(1997)
Source URL:
First approved in 1997
Source:
GENESA by GENSIA AUTOMEDICS
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Arbutamine was indicated to elicit acute cardiovascular responses in order to aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately. Arbutamine is a synthetic catecholamine with positive chronotropic and inotropic properties. The chronotropic (increase in heart rate [HR]) and inotropic (increase in force of contraction) effects of arbutamine serve to mimic exercise by increasing cardiac work (producing stress) and provoke myocardial ischemia in patients with compromised coronary arteries. In functional assays, arbutamine is more selective for beta-adrenergic receptors than for alpha-adrenergic receptors. The beta-agonist activity of arbutamine provides cardiac stress by increasing HR, cardiac contractility, and systolic blood pressure.
Status:
US Previously Marketed
Source:
HEXABRIX by GUERBET
(1985)
Source URL:
First approved in 1985
Source:
HEXABRIX by GUERBET
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Ioxaglate Sodium Meglumine (trade name Hexabrix) is a new low osmolality ionic contrast agent, that used as a diagnostic radiopaque medium. Following intravascular injection, Ioxaglate Sodium Meglumine is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine. The joint spaces as well as the uterus and fallopian tubes may be visualized by the direct injection of the contrast medium into the region to be studied. The usual adult dose for left coronary arteriography is 8 mL (range 2-14 mL) and for right coronary arteriography is 5 mL (range 1-10 mL). The doses may be repeated as necessary Patients may have clinically insignificant ECG changes during the procedure. The following adverse effects have occurred in conjunction with the administration of iodinated intravascular contrast agents for this procedure: hypotension, shock, anginal pain, myocardial infarction, cardiac arrhythmias (bradycardia, ventricular tachycardia, ventricular fibrillation) and cardiac arrest.
Status:
US Previously Marketed
First approved in 1960
Class (Stereo):
CHEMICAL (RACEMIC)
Triparanol (brand and developmental code names MER/29) is a 24-dehydro cholesterol reductase inhibitor, which is an enzyme involved in the biosynthesis of cholesterol. It has antitumor properties, such as decreasing proliferation and inducing apoptosis in many cancer cell lines and slowing tumor growth in a mouse xenograft model. It can also decrease Hedgehog pathway signaling in cancer cells. Triparanol was the first synthetic cholesterol-lowering drug. It was withdrawn in 1962 due to severe adverse effects such as nausea and vomiting, vision loss due to irreversible cataracts, alopecia, skin disorders (e.g., dryness, itching, peeling, and "fish-scale" texture), and accelerated atherosclerosis and is now considered to be obsolete.
Status:
Possibly Marketed Outside US
Source:
TECHNETIUM TC 99M SESTAMIBI
Source URL:
First approved in 1990
Source:
NDA019785
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Chromonar is a coronary vasodilator agent, it dilates coronary vessels and increases coronary blood flow volume rate, contributes to the development of collateral circulation (with prolonged use), improves metabolic processes in myocardium. The mechanism of action of a role played by its inhibitory effect on phosphodiesterase, accompanied by accumulation in the cells of cyclic 3 ', 5'-adenosine monophosphate. Due to the relatively low therapeutic efficacy Chromonar use is limited, mainly in the early stages of coronary heart disease with angina pectoris in the absence of long-standing and long strokes, when there is no expressed stenotic process.